A Phase 1 Study of GS-0189 (formerly FSI-189) as Monotherapy and in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
|Effective start/end date
|11/16/21 → 11/16/26
- GILEAD SCIENCES, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.